

Press Release

September 12, 2017 4:30 pm CET

Skanska signs second major lease at 121 Seaport in Boston, USA, now 100 percent leased

Skanska has signed a lease with Alexion Pharmaceuticals, Inc. for about 150,000 square feet, 14,000 square meters, at its 121 Seaport office development in Boston, USA. The lease agreement is for 13 years and occupancy will take place in June 2018, when Alexion moves its headquarters to 121 Seaport. The building is now 100 percent leased.

Alexion is a global biopharmaceutical company focused on developing and delivering life-changing therapies for patients with rare diseases.

Located in Boston's Innovation District, <u>121 Seaport</u> is a 17-story, 400,000-square-foot, 37,000-square-meter, Class-A office building, targeting LEED Platinum certification. The building is on target for completion in the first quarter of 2018.

Skanska is one of the leading development and construction companies in USA, specialized in building construction, civil infrastructure and developing commercial properties in select U.S. markets. Skanska also offers services in public-private partnerships. Skanska USA had sales of SEK 59 billion in 2016 and had about 9,300 employees in its operations.

For further information please contact:

Beth Miller, Communications, Skanska USA, tel +1 917 438 4523 Andreas Joons, Press Officer, Skanska AB, tel +46 (0)10 449 04 94 Direct line for media, tel +46 (0)10 448 88 99

This and previous releases can also be found at www.skanska.com

Skanska is one of the world's leading construction and project development companies, focused on selected home markets in the Nordic region, Europe and USA. Supported by global trends in urbanization and demographics, and by being at the forefront in sustainability, Skanska offers competitive solutions for both simple and the most complex assignments, helping to build a sustainable future for customers and communities. The Group has about 41,000 employees. Skanska's sales in 2016 totaled SEK 151 billion.